Skip to main content

Waters Q2 Organic Sales Grow 8 Percent, Though Profit Slides 10 Percent

NEW YORK, July 26 (GenomeWeb News) - Waters today said that second-quarter sales increased around 8 percent organically atop increasing R&D spending and a 10-percent slide in net profits.


Still, the company's stock was up more than 9 percent, or $3.80, at $44.50 in heavy trading Tuesday afternoon because the profit beat analysts' consensus estimate.


Total sales for the period ended July 2 increased 9 percent to $284.6 million from $260.5 million year over year, Waters said. Approximately 1 percent of the growth was the result of favorable foreign-currency exchange rates.


R&D spending in the period increased around 5 percent to $16.5 million from $15.7 million in the year-ago quarter.


Net income, however, slid almost 10 percent to $54 million, or $.47 per basic share, from $59.8 million, or $.50 per basic share, year over year.


Waters said it had around $615 million in cash and equivalents as of July 2.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.